Products Description
English name：Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer
CAS number：189261-10-7
Molecular formula: C40H55N7O11S
Molecular weight: 841.97
EINECS No
Related category: chemical reagents
The Mol file: 189261-10-7.mol
Structural formula:
That alizumab properties
Storage conditions: Store at 4 C, do not freeze
Form: liquid
Color: colorless to pale yellow
Use and synthesis method of natalizumab
Bioactivity
Natalizumab Is a recombinant humanized monoclonal antibody that binds to α 4 β 1-intein (α 4 β 1-integrin) and blocks its Chemicalbook interaction with Vascular cell adhesion molecule 1 (VCAM-1). Natalizumab It can be used in the study of relapsed-remitting multiple sclerosis and Crohn's disease. Natalizumab Can also prevent lymphocytes from entering the CNS, thus preventing acute demyelination recurrence.
In vitro study
Natalizumab, a recombinant, humanized antibody, binds to α4β1-integrin and blocks its interaction with VCAM-1. As a result, leukocyte migration into brain tissue is inhibited, reducing inflammation and preventing the formation of lesions. Natalizumab may also inhibit ongoing central nervous system (CNS) inflammation, mediated by leukocytes already present in the CNS, by interrupting the interactions between α4-integrin-expressing leukocytes and extracellular matrix proteins such as fibronectin and osteopontin.
In vivo research
Natalizumab binds rapidly and with high affinity to α4-integrin. Maximal binding (≥80% saturation), measured in vitro on isolated lymphocyte membranes, occurred 24 hours after intravenous (IV) doses of natalizumab 1 mg/kg to 6 mg/kg.
Security information
Toxic substance data: 189261-10-7 (Hazardous Substances Data)
Hot Tags: natalizumab monoclonal antibody, China natalizumab monoclonal antibody suppliers, 1256937-27-5, Ocrelizumab Is Being Studied in Multiple Sclerosis, 1189541-98-7, 189261-10-7, Research Grade Casirivimab, Reatment Of Psoriasis with Secukinumab Antagonist
